Read about cancer treatment options listed by gene mutation, type of cancer and type of treatment.
I am here to learn about:

Genetic Testing

Biomarker Testing

Genetics and Breast Cancer

Genetics and Pancreatic Cancer

Lynch Syndrome

I've Tested Positive, Now What?

Information for Healthcare Professionals

Men with Mutations

Women with Mutations

Managing Menopause

Genetics and Prostate Cancer

Genetics and Ovarian Cancer

Genetics and Endometrial Cancer

Genetics and Colorectal Cancer

Information for Researchers

Risk Management & Treatment

Cancer Treatment > Biomarker Testing > Common Biomarker Tests

1
Overview
2
Common Biomarker Tests
3
DNA Damage Repair

Biomarkers used for treatment selection

The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other biomarker tests and treatments, which may be available. 

Biomarker Cancer Treatment/s
  Breast Colorectal Endometrial Melanoma Ovarian Pancreatic Prostate

 
BRAFV600E   X   X      

Braftovi (encorafenib)
Braftovi in combination with Mektovi (binimetinib)
Cotellic (cobimetinib)
Zelboraf (vemurafenib) 
BRCA1, BRCA2          X   X Lynparza (olaparib) 
Rubraca (rucaparib)
Zejula® (niraparib)
Epidermal growth factor
receptor (EGFR) mutation testing		   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 
Estrogen/Progesterone receptor
(ER/PR) expression		 X   X        

Aromatase inhibitors (AIs)
Tamoxifen
Raloxifene
Her2neu overexpression X             Herceptin (trastuzumab)
Perjeta (pertuzumab)
Tuksya (tucatinib)
Kadcyla (ado-trastuzumab emtansine) 
Homologous Recombination
Deficiency (HRD)		         X    

Lynparza (olaparib) 
Zejula® (niraparib)
Homologous Recombination Response (HRR) pathway mutations (ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK2, FANCL, PALB2, RAD51B, RAD51C,  RAD51D, RAD54)             X Lynparza (olaparib) 
KRAS mutation   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 
MSI-H (Microsatellite Instability) or dMMR/MMR-D (Mismatch Repair Deficient) X X X X X X X Keytruda (pembrolizumab)
MSI-H (Microsatellite Instability) or dMMR/MMR-D (Mismatch Repair Deficient)   X           Opdivo (nivolumab) 
Yervoy (ipilimumab)
dMMR/MMR-D (Mismatch Repair Deficient)     X         Jemperli (dostarlimab)
NTRK fusion X X X X X X X Vitrakvi (larotrectinib)
PDL1 expression X             Tecentriq (atezolizumab)
PIK3CA X             Piqray (alpelisib),
Tumor Mutational Burden (TMB) X X X X X X X Keytruda (pembrolizumab)
Last updated July 05, 2020